What is Ozempic?
Ozempic is the brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It belongs to a class of medications called incretin mimetics, which work by:
-
Stimulating insulin secretion from pancreatic beta cells
-
Suppressing glucagon release (which lowers blood sugar)
-
Slowing gastric emptying (leading to prolonged satiety)
-
Reducing appetite through direct action on brain receptors
FDA-Approved Uses
-
Type 2 Diabetes Management (Primary Indication):
-
Improves glycemic control in adults
-
Reduces HbA1c by 1.0-1.8%
-
Lowers risk of major cardiovascular events
-
-
Off-Label Uses:
-
Chronic weight management (higher doses under brand Wegovy)
-
PCOS-related insulin resistance
-
Non-alcoholic steatohepatitis (NASH) research
-
Dosage Forms & Strengths
-
Prefilled Multi-Dose Pens:
-
0.25 mg/0.5 mg dose pen (starter dose)
-
1 mg dose pen
-
2 mg dose pen (newest FDA-approved higher dose)
-
-
Administration:
-
Subcutaneous injection (abdomen, thigh, or upper arm)
-
Once weekly (any time of day, with/without meals)
-